SINO BIOPHARMACEUT HKD0.025 (SBMFF) Receives Consensus Rating of “Sell” from Brokerages
Shares of SINO BIOPHARMACEUT HKD0.025 (NASDAQ:SBMFF) have been given an average broker rating score of 4.00 (Sell) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a sell rating.
Zacks has also assigned SINO BIOPHARMACEUT HKD0.025 an industry rank of 106 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research raised shares of SINO BIOPHARMACEUT HKD0.025 from a “hold” rating to a “buy” rating and set a $1.00 target price for the company in a research note on Saturday, August 26th.
TRADEMARK VIOLATION NOTICE: This story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/10/21/sino-biopharmaceut-hkd0-025-sbmff-receives-consensus-rating-of-sell-from-brokerages.html.
SINO BIOPHARMACEUT HKD0.025 (SBMFF) traded up 4.50% on Friday, hitting $1.16. 43,220 shares of the stock were exchanged. The firm has a market cap of $8.60 billion and a P/E ratio of 29.74. SINO BIOPHARMACEUT HKD0.025 has a 12 month low of $0.72 and a 12 month high of $1.16. The company has a 50-day moving average of $1.05 and a 200 day moving average of $0.88.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SINO BIOPHARMACEUT HKD0.025 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SINO BIOPHARMACEUT HKD0.025 and related companies with MarketBeat.com's FREE daily email newsletter.